Searched for
MOLNUPIRAVIR BENEFITS
Divi’s Labs Q3 preview: PAT may grow 33% YoY on favourable base; outlook eyedThe consolidated net profit for the quarter is seen rising 33% YoY to Rs 407.40 crore, according to the average of estimates given by five ...- New study finds link between Covid antiviral drug & virus mutationsA study published in the journal Nature has found a link between the COVID-19 antiviral drug molnupiravir and a pattern of mutations in the...
- Molnupiravir doesn't help reduce deaths or hospital admissions: StudyPrevious studies among unvaccinated patients had suggested that molnupiravir could help prevent hospital admission. The latest study provid...
- US FDA study warns against certain treatments for Omicron. Details hereWith the continuous rise in Omicron cases of Covid-19, patients are looking at various drug options to relieve some symptoms. US-based infe...
- COVID antiviral Molnupiravir to be tested in RECOVERY trial on hospitalised patientsThe RECOVERY Trial was launched as an emergency response in March 2020 and has so far discovered three effective treatments for COVID-19 - ...
- Molnupiravir not included in COVID-19 treatment guidelines as its harms outweigh benefits: ICMRNoting its rampant and irrational use of the pill, Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) said that e...
- With limited options, doctors and hospitals start prescribing Molnupiravir for high-risk patientsThe latest surge of Covid cases is largely fuelled by the Omicron variant, even as the Delta is spreading albeit at a lower intensity.
- Do Molnupiravir's benefits outweigh risks? Here's what experts sayThe ICMR Director-General Balram Bhargava had said that molnupiravir has major safety concerns and has not been included in the national pr...
- Molnupiravir not to be included in COVID-19 clinical management protocol as of nowThe experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at th...
- Mild Covid cases can be managed at home, Molnupiravir no magic drug, says AIIMS docDr Nischal said, "Pandemic does not mean that unless your doctor prescribes multiple drugs or fancy pills you are not going to get okay. At...
- Covid-19 drug Molnupiravir flagged for 'major safety concerns'Molnupiravir has major safety concerns including teratogenicity, mutagenicity, muscle and bone damage.
- Covid cases on the rise, experts call for newer drugs, faster approvalsThe Drug Controller General of India had last week approved Merck and Ridgeback’s antiviral molnupiravir for the treatment of mild-to-moder...
- Govt panel weighing risks and benefits of Merck's Covid drugThe Subject Expert Committee (SEC) under the drug regulator of India has asked manufacturers in India to specify the category of Covid pati...
- What COVID-19 therapies are available in US?The U.S. recently added two new weapons to its small arsenal against the coronavirus: pills that patients can take at home to treat COVID-1...
- USFDA okays Merck's Covid Drug for use in high-risk casesThe USFDA also said molnupiravir should be given to those for whom alternative Covid-19 treatment options authorised by it are not accessib...
- USFDA approves COVID antiviral pill molnupiravir for emergency useThe USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or cl...
- Merck v Pfizer: here's how the two new COVID antiviral drugs work and will be usedUK approved molnupiravir, the COVID antiviral developed by Merck and Ridgeback Therapeutics. Now, Pfizer has released results from trials o...
- Final US hurdle for Merck's COVID-19 pill: FDA panel reviewIf authorized, Merck's pill would be the first that U.S. patients could take at home to ease symptoms and speed recovery, a major step towa...
- COVID antiviral drug Molnupiravir efficacy against hospitalization or death drops to 30% compared to placebo groupThe analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...
- Natco Seeks emergency approval to launch Molnupiravir for Covid-19 in IndiaMolnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...
Load More
